In vitro treatment of congenital disorder of glycosylation type Ia using PLGA nanoparticles loaded with GDP‑Man

6Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Congenital disorder of glycosylation (CDG) type Ia is a multisystem disorder that occurs due to mutations in the phosphomannomutase 2 (PMM2) gene, which encodes for an enzyme involved in the N-glycosylation pathway. Mutated PMM2 leads to the reduced conversion of mannose-6-P to mannose-1-P, which results in low concentration levels of guanosine 5'-diphospho-D-mannose (GDP-Man), a nucleotide-activated sugar essential for the construction of protein oligosaccharide chains. In the present study, an in vitro therapeutic approach was used, based on GDP-Man-loaded poly (D,L-lactide-co-glycolide) (PLGA) nanoparticles (NPs), which were used to treat CDG-Ia fibroblast cultures, thus bypassing the glycosylation pathway reaction catalysed by PMM2. To assess the degree of hypoglycosylation in vitro, the present study examined the activities of α-mannosidase, β-glucoronidase and β-galactosidase in defective and normal fibroblasts. GDP‑Man (30 µg/ml GDP-Man PLGA NPs) was incubated for 48 h with the cells and the specific activities of α-mannosidase and β-galactosidase were estimated at 69 and 92% compared with healthy controls. The residual activity of β‑glucoronidase increased from 6.5 to 32.5% and was significantly higher compared with that noted in the untreated CDG‑Ia fibroblasts. The glycosylation process of fibroblasts was also analysed by two-dimensional electrophoresis. The results demonstrated that treatment caused the reappearance of several glycosylated proteins. The data in vitro showed that GDP‑Man PLGA NPs have desirable efficacy and warrant further evaluation in a preclinical validation animal model.

Cite

CITATION STYLE

APA

Bortot, B., de Martino, E., Tesser, A., Ura, B., Ruozi, B., Aloisio, M., … Severini, G. M. (2019). In vitro treatment of congenital disorder of glycosylation type Ia using PLGA nanoparticles loaded with GDP‑Man. International Journal of Molecular Medicine, 44(1), 262–272. https://doi.org/10.3892/ijmm.2019.4199

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free